Drug Trial Radar · NCT07093710
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Aug 1, 2027
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
Conditions
- Peripheral T Cell Lymphoma
Interventions
GolidocitinibDrug
150mg, po, qd;
Mitoxantrone Hydrochloride LiposomeDrug
Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)
ChidamideDrug
Cohort 2: Chidamide:20mg/30mg, po, Biw (phase Ib); RP2D (phase II study)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate(ORR) for Phase 2Time frame: Up to 24 months
- Maximum tolerated dose (MTD) for Phase 1bTime frame: The first cycle after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.